United States Artificial Insemination Market Report by Type, Source Type, End Use, States and Company Analysis 2026-2034

United States Artificial Insemination Market Size and Forecast

United States Artificial Insemination Market will grow from US$ 620.43 Million in 2025 to US$ 1,151.23 Million in 2034, at a Compound Annual Growth Rate (CAGR) of 7.11% from 2026–2034. Market growth is supported by increasing infertility rates, delayed parenthood, rising awareness of assisted reproductive technologies, and growing acceptance of fertility treatments. Technological advancements in sperm processing, fertility clinics, donor programs, and improved reproductive healthcare access are further contributing to market expansion across the United States.

What is Artificial Insemination and its Uses & Popularity in the United States

Artificial insemination (AI) is an assisted reproductive technique in which prepared sperm is deliberately placed into a woman’s reproductive tract to improve the probability of fertilization. The most common form is intrauterine insemination (IUI), where concentrated sperm is inserted directly into the uterus around the time of ovulation. Artificial insemination may use sperm from a partner or a donor and can be performed with or without fertility medications.

In the United States, it is used for unexplained infertility, ovulation-related fertility problems, cervical-factor infertility, certain male-factor infertility conditions, and donor-sperm conception. It is also an option for single women and same-sex female couples seeking pregnancy. Growing awareness of fertility preservation and assisted reproductive technologies is supporting demand. According to the CDC, 2.8% of U.S. infants born in 2021—more than 97,000 births—were conceived using assisted reproductive technology (ART), although ART is broader than artificial insemination and primarily includes procedures such as IVF. The availability of fertility clinics, sperm banks, reproductive specialists, improved sperm-processing techniques, and increasing acceptance of fertility treatment has strengthened the role of artificial insemination within the U.S. reproductive healthcare ecosystem.

Number of Births per 1,000 Women Ages 15–44

• 2000: Approximately 65.9 births per 1,000 women
• 2002: Approximately 65.0 births per 1,000 women
• 2004: Approximately 66.2 births per 1,000 women
• 2006: Approximately 68.5 births per 1,000 women
• 2008: Approximately 68.1 births per 1,000 women
• 2010: Approximately 64.1 births per 1,000 women
• 2012: Approximately 63.0 births per 1,000 women
• 2014: Approximately 62.9 births per 1,000 women
• 2016: Approximately 62.0 births per 1,000 women
• 2018: Approximately 59.0 births per 1,000 women
• 2020: Approximately 55.8 births per 1,000 women
• 2022: Approximately 56.0 births per 1,000 women
• 2024: 53.8 births per 1,000 women
• 2025: 53.1 births per 1,000 women

Source: U.S. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS).

Growth Drivers for the United States Artificial Insemination Market

Rising Infertility and Growing Demand for Fertility Treatment

Increasing infertility and delayed family formation are major factors supporting the U.S. artificial insemination market. Infertility affects a substantial share of reproductive-age adults, creating demand for medical interventions ranging from ovulation management and artificial insemination to IVF. CDC data indicate that approximately 19% of married women aged 15–49 with no prior births experienced infertility in 2015–2019, while around 6% of married women in this age group were unable to become pregnant after 12 months of trying. Infertility can involve female or male reproductive factors, and artificial insemination provides a comparatively less invasive treatment option for selected patients.  Delayed childbearing also contributes to fertility-treatment demand because fertility generally declines with increasing maternal age. Artificial insemination can be used with ovulation-inducing medications and carefully timed sperm placement, making it useful for certain ovulatory and unexplained infertility cases. Greater awareness of available fertility services, improved diagnosis, and expanding access to reproductive specialists are therefore encouraging more individuals and couples to consider assisted conception, supporting continued market growth.

Increasing Acceptance of Donor Sperm and Diverse Family-Building Options

Growing acceptance of donor conception and expanding family-building options are creating additional opportunities for the U.S. artificial insemination market. Artificial insemination can enable conception using donor sperm and is therefore relevant to single women, same-sex female couples, and heterosexual couples affected by certain male-factor infertility conditions. The CDC reports that approximately 1 in 5 women of reproductive age in the United States have never given birth and may experience infertility or difficulty carrying a pregnancy, highlighting the importance of accessible reproductive options.  Fertility services have also become increasingly integrated with sperm banks, reproductive endocrinology clinics, and specialized fertility centers. Improvements in donor screening, sperm cryopreservation, laboratory preparation, and digital donor-selection platforms have increased the practicality of donor insemination. Social acceptance of diverse family structures is also encouraging broader utilization of fertility services. In addition, improved counseling and patient education help individuals understand treatment options and success factors. These demographic, technological, and social trends are expanding the potential patient base for artificial insemination beyond traditional infertility treatment and supporting demand for donor-based reproductive services across the United States.

Technological Improvements in Sperm Processing and Reproductive Care

Technological advancements in reproductive medicine are improving the efficiency, safety, and convenience of artificial insemination procedures. Modern fertility laboratories can evaluate and prepare sperm samples using techniques designed to concentrate motile sperm and remove unwanted components before insemination. Ovulation monitoring through ultrasound, hormone testing, and fertility-tracking methods also enables clinicians to better time insemination around the fertile window. The broader U.S. assisted-reproduction sector demonstrates strong demand for advanced fertility services: CDC surveillance reported 97,128 infants born in 2021 following ART, representing 2.8% of all U.S. infants born that year.  Although ART statistics primarily cover IVF and related procedures rather than conventional artificial insemination, they illustrate the increasing integration of reproductive technologies into U.S. healthcare. Fertility clinics are also adopting digital patient-management systems, telehealth consultations, improved laboratory quality controls, and cryopreservation technologies. These developments can make fertility treatment more organized and accessible while improving clinical decision-making. Continued innovation in sperm selection, reproductive monitoring, laboratory processing, and patient support is expected to strengthen the position of artificial insemination within the wider U.S. fertility-treatment market.

Challenges in the United States Artificial Insemination Market

Variable Success Rates and Multiple Treatment Cycles

Variable treatment success rates remain a major challenge for the U.S. artificial insemination market. The effectiveness of IUI depends on several factors, including female age, ovarian reserve, ovulation status, sperm quality, infertility cause, use of fertility medications, and timing of insemination. Consequently, one treatment cycle may not result in pregnancy, requiring patients to undergo multiple cycles or progress to more advanced procedures such as IVF. Younger patients generally have better prospects than older patients, while severe male-factor infertility or significant reproductive disorders may reduce the suitability of IUI. The CDC emphasizes that fertility treatment outcomes vary according to patient and treatment characteristics, and ART success rates differ considerably by age and other factors.  Repeated unsuccessful procedures can increase financial costs, emotional stress, and treatment fatigue. Patients may also require additional diagnostic testing or medication before clinicians determine whether artificial insemination is appropriate. Healthcare providers therefore need to carefully select candidates and communicate realistic expectations. Variability in outcomes can influence patient satisfaction and may encourage some consumers to move more quickly toward higher-cost assisted reproductive procedures.

High Treatment Costs, Access Gaps, and Insurance Limitations

Treatment affordability and unequal access remain important barriers to the growth of artificial insemination services in the United States. Fertility care can involve consultation fees, diagnostic testing, ovulation medications, sperm preparation, donor sperm, laboratory procedures, and multiple treatment cycles. Insurance coverage also varies considerably by state, employer, and health plan, meaning that some patients must pay substantial out-of-pocket expenses. The CDC notes that access to infertility services can be affected by factors including cost, insurance coverage, geographic availability, and socioeconomic circumstances.  These barriers can disproportionately affect lower-income households and individuals living in areas with fewer fertility specialists or reproductive healthcare facilities. Donor sperm and cryopreservation can add further expenses for patients pursuing donor insemination. Although telehealth and expanded fertility networks are improving access, specialist availability remains concentrated in major metropolitan areas. High costs may also encourage patients to delay treatment or discontinue after unsuccessful cycles. Improving insurance coverage, expanding fertility services beyond large urban centers, and increasing transparent pricing could help reduce these barriers and broaden access to artificial insemination across the United States.

Artificial Insemination Launches and Developments in the USA

1. FemaSeed Intratubal Insemination – U.S. Commercial Launch
   Femasys began commercializing FemaSeed in the U.S. in 2024 following FDA 510(k) clearance in September 2023. The device delivers prepared sperm directly toward the fallopian tube and is designed as an alternative to conventional IUI for selected infertility patients.
2. FemaSeed–Boston IVF Partnership
   In October 2024, Femasys partnered with Boston IVF to make FemaSeed available across nearly 30 U.S. fertility centers, expanding access to intratubal insemination for patients with infertility.
3. FemaSeed–HRC Fertility Expansion
   Femasys expanded FemaSeed availability through a partnership with HRC Fertility, broadening access to its localized artificial-insemination technology within a major U.S. fertility-care network.
4. FemaSeed–CNY Fertility Partnership
   In 2025, Femasys announced a partnership with CNY Fertility to expand availability of FemaSeed, supporting wider adoption of intratubal insemination as a fertility-treatment option.
5. PherDal FDA-Cleared At-Home Insemination Kit
   PherDal launched its FDA-cleared, sterile at-home intravaginal insemination kit in the U.S. in January 2024. The kit includes sterile syringes and collection cups and is designed to provide an at-home option for insemination.
6. Aetna Expanded IUI Coverage
   In September 2024, Aetna expanded IUI coverage for eligible plans, making intrauterine insemination available as a covered medical benefit regardless of fertility status under the updated policy. The change was intended to improve access for diverse family-building needs.
7. CCRM Fertility Jersey City IUI Services
   CCRM Fertility opened a new Jersey City location in January 2024 offering a comprehensive range of fertility services, including IUI, donor sperm, LGBTQ+ family building, egg freezing, and IVF.
8. Baptist Health Paducah IUI Service Expansion
   In October 2025, Baptist Health Paducah expanded local fertility care by introducing IUI services. The program allows patients to receive insemination locally rather than traveling to larger fertility centers.
9. Delaware Institute for Reproductive Medicine Fertility Center
   The Delaware Institute for Reproductive Medicine opened a new fertility center in Newark offering IUI alongside IVF, donor sperm and egg services, fertility testing, LGBTQ+ family building, and egg freezing.
10. MySpermBank Donor-Sperm Platform
    In May 2026, Inception Fertility launched MySpermBank, a digital-first donor-sperm platform designed to simplify donor discovery and selection. The service supports the broader donor-insemination ecosystem and expands access to donor sperm across the U.S. and Canada.

California Strong Fertility Infrastructure and Treatment Demand

California is a leading market for artificial insemination, supported by its large population, advanced healthcare infrastructure, and extensive fertility-care ecosystem. CDC state surveillance recorded 3,540 ART procedures per 1 million women aged 15–49 in California in 2022, above the U.S. national rate of 3,301. California also had one of the largest fertility-clinic networks historically, with 72 reporting ART clinics in 2019, demonstrating its strong reproductive-health infrastructure. Los Angeles, San Francisco, San Diego, and other metropolitan areas provide access to fertility specialists, donor sperm programs, IUI, IVF, fertility testing, and reproductive counseling. Demand is supported by delayed parenthood, infertility awareness, and growing acceptance of assisted reproduction among single parents and same-sex couples. Advanced sperm preparation, ovulation monitoring, cryopreservation, and digital consultations further improve treatment accessibility. California’s combination of medical expertise, diverse patient demographics, and technology-oriented healthcare services strengthens its position as a major U.S. artificial insemination market.

Texas Expanding Fertility-Care Infrastructure

Texas represents an important and expanding artificial insemination market, supported by its large population and growing availability of reproductive healthcare services. CDC data show that Texas recorded 2,752 ART procedures per 1 million women aged 15–49 in 2022. The state has also maintained one of the largest fertility-clinic networks in the country, with 42 reporting ART clinics in 2019. Houston, Dallas–Fort Worth, Austin, and San Antonio host fertility centers offering IUI, IVF, donor sperm services, fertility diagnostics, and reproductive counseling. Delayed childbearing, infertility awareness, and increasing acceptance of assisted reproductive options support demand. Clinics are also adopting digital scheduling, telehealth consultations, ultrasound monitoring, and personalized treatment planning. Expanding services beyond major metropolitan areas can improve access for patients in suburban and rural communities. These factors, combined with Texas’s substantial population and developing healthcare infrastructure, make the state an important growth market for artificial insemination and related fertility services.

New York High Treatment Utilization and Specialized Healthcare

New York is a significant market for artificial insemination because of its dense population, sophisticated healthcare system, and concentration of fertility specialists. CDC surveillance reported 6,277 ART procedures per 1 million women aged 15–49 in New York in 2022, substantially above the national rate of 3,301. New York also recorded 6,277 procedures per million women, placing it among the states with relatively high ART utilization. New York City and other metropolitan areas provide extensive access to fertility clinics offering IUI, IVF, donor sperm, fertility preservation, reproductive testing, and counseling. Delayed parenthood, career-oriented lifestyles, and greater awareness of infertility treatments contribute to demand. The state’s fertility ecosystem also supports single parents and same-sex couples seeking family-building services. Telemedicine, digital appointment systems, advanced laboratory services, and personalized fertility monitoring improve convenience. The combination of high healthcare accessibility, specialized expertise, and strong demand for reproductive services reinforces New York’s importance within the U.S. artificial insemination market.

Florida Growing Fertility Services and Patient Demand

Florida’s artificial insemination market benefits from its large and diverse population, expanding healthcare network, and increasing awareness of fertility treatments. CDC data indicate that Florida recorded 2,566 ART procedures per 1 million women aged 15–49 in 2022. The state had a substantial fertility-care infrastructure supporting ART services, although the CDC figures encompass ART broadly rather than IUI specifically. Miami, Orlando, Tampa, Jacksonville, and South Florida have established fertility centers offering IUI, IVF, donor sperm, fertility testing, and reproductive counseling. Demand is supported by delayed parenthood, infertility awareness, and increasing acceptance of assisted reproductive technologies among diverse family structures. Clinics are increasingly emphasizing personalized treatment plans, ovulation monitoring, sperm preparation, and digital patient services. Telehealth can also improve consultation access for patients outside major metropolitan areas. Florida’s combination of population growth, medical infrastructure, technology adoption, and expanding fertility awareness supports its role as an important contributor to the U.S. artificial insemination market.

United States Artificial Insemination Market Segments:

Type

• Intrauterine
• Intracervical
• Intravaginal
• Intratubal

Source Type

• AIH-Husband
• AID-Donor

End Use

• Hospitals and Clinics
• Fertility Centers
• Other End Users

States – Market breakup in 29 viewpoints:

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All companies have been covered from 5 viewpoints:

• Company Overview
• Key Persons
• Recent Development & Strategies
• SWOT Analysis
• Sales Analysis

Key Players Analysis

• Vitrolife
• Genea Pty Limited
• Rinovum Women’s Health, LLC
• Pride Angel
• HI-TECH SOLUTIONS
• FUJIFILM Irvine Scientific
• Kitazato Corporation
• Rocket Medical plc
• Conceivex, Inc.

Report Details: